Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Fuji
Harvard Business School
Queensland Health
Boehringer Ingelheim
Citi
McKesson
Argus Health

Generated: December 19, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VICKS FORMULA 44

« Back to Dashboard

Clinical Trials for Vicks Formula 44

Trial ID Title Status Sponsor Phase Summary
NCT00000574 Ibuprofen in Sepsis Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.
NCT00000574 Ibuprofen in Sepsis Study Completed Vanderbilt University Medical Center Phase 3 To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.
NCT00000873 A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A This study examines the effects of an infant formula containing increased calories, as compared to commercial formulas, when given during the first 6 months of life. It will examine effects on growth, disease progress, immune system, and quality of life of infected infants. HIV disease in infants often leads to nutritional deficiencies. Providing increased nutrition early in their lives may help the quality of life of children who contract HIV from their mothers.
NCT00000873 A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A This study examines the effects of an infant formula containing increased calories, as compared to commercial formulas, when given during the first 6 months of life. It will examine effects on growth, disease progress, immune system, and quality of life of infected infants. HIV disease in infants often leads to nutritional deficiencies. Providing increased nutrition early in their lives may help the quality of life of children who contract HIV from their mothers.
NCT00000981 The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS Completed Oclassen Pharmaceuticals Phase 2 To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient population; and to determine pharmacokinetics following multiple doses of FIAC. (An example of another nucleoside analog effective against retroviruses such as HIV is zidovudine (AZT).) CMV infection is a medically significant opportunistic disease in patients with HIV-related infection. The purine nucleoside ganciclovir has been used to treat AIDS patients with CMV disease. Although ganciclovir is useful in treating CMV disease, such treatment is frequently complicated by hematologic (blood) toxicity. Also, treatment is difficult because it requires daily intravenous dosing. Test tube studies show that FIAC and its primary breakdown product FIAU are highly and specifically active against several viruses including CMV. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vicks Formula 44

Condition Name

Condition Name for Vicks Formula 44
Intervention Trials
HIV Infections 9
Obesity 8
Healthy 7
Anemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vicks Formula 44
Intervention Trials
Syndrome 25
Kidney Diseases 20
Diabetes Mellitus 15
Renal Insufficiency 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vicks Formula 44

Trials by Country

Trials by Country for Vicks Formula 44
Location Trials
United States 436
China 95
Italy 26
Brazil 23
Canada 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vicks Formula 44
Location Trials
Texas 25
New York 25
California 25
Maryland 23
Illinois 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vicks Formula 44

Clinical Trial Phase

Clinical Trial Phase for Vicks Formula 44
Clinical Trial Phase Trials
Phase 4 118
Phase 3 69
Phase 2/Phase 3 28
[disabled in preview] 145
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vicks Formula 44
Clinical Trial Phase Trials
Completed 246
Recruiting 111
Unknown status 53
[disabled in preview] 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vicks Formula 44

Sponsor Name

Sponsor Name for Vicks Formula 44
Sponsor Trials
Hoosier Cancer Research Network 17
National Institute of Allergy and Infectious Diseases (NIAID) 11
Shanghai University of Traditional Chinese Medicine 9
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vicks Formula 44
Sponsor Trials
Other 727
Industry 155
NIH 54
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Moodys
Federal Trade Commission
Medtronic
Fish and Richardson
QuintilesIMS
Fuji
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.